Response Depth in High-Risk Smoldering Multiple Myeloma May Predict Outcomes

Efficacy results from the trial reveal that at a median follow-up of 50 months (range, 8-61) the primary end point of progression-free survival was not reached (NR; 95% CI, 57.7-NR). #mmsm | @OmarNadeemMD https://t.co/vdbJmf3sOP